Malignant lymphomas

Indication for 22-Oxovincaleukoblastine

Population group: Suitable for both men and women, only adults (18 years old or older)

Malignant lymphomas, including Hodgkin’s disease and non-Hodgkin’s lymphomas.

For this indication, competent medicine agencies globally authorize below treatments:

1.4-1.5 mg/m² once weekly

Route of admnistration


Defined daily dose

1.4 - 1.5 mg per m² of body surface area (BSA)

Dosage regimen

From 1.4 To 1.5 mg per m² of body surface area (BSA) once every 7 day(s)

Detailed description

The drug is administered intravenously at weekly intervals. The recommended dose is 1.4 to 1.5 mg/m² up to a maximum weekly dose of 2 mg.

Active ingredient

Vincristine is an antineoplastic drug with broad-spectrum anti-tumor activity in man. The drug may act by mitotic inhibition, causing an arrest of cell division in metaphase.

Read more about 22-Oxovincaleukoblastine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner